杭州天目山药业股份有限公司2025 年半年度报告 公司代码：600671 公司简称：天目药业 杭州天目山药业股份有限公司 杭州天目山药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人刘加勇、主管会计工作负责人冷亮及会计机构负责人（会计主管人员）王一惠 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细描述公司可 ...

Core Viewpoint - Tianmu Pharmaceutical has made significant progress in product registration and market adaptation, focusing on innovative health products while addressing investor concerns about its growth strategy and market positioning [2][3][4]. Group 1: Financial Performance - As of August 8, 2025, Tianmu Pharmaceutical's stock closed at 14.91 yuan, up 2.12%, with a trading volume of 66,600 shares and a transaction value of 98.26 million yuan [1]. - The company reported a significant improvement in its financial performance, with a net profit margin exceeding 22% in 2024, and the stock price increased by over 50% from the end of 2024 to June 2025 [4]. Group 2: Product Development and Market Strategy - The company has received production licenses for approximately 40 new drugs, with six products currently in production and sales, including sugar-free formulations to cater to market demands [2][3]. - Tianmu Pharmaceutical is actively conducting market research to prioritize the production of drugs with high market demand and favorable prospects, aiming to enhance product diversity and applicability [3]. - The company is also exploring collaborations with well-known manufacturers to innovate health products that combine traditional Chinese medicine with consumer goods [3]. Group 3: Investor Relations and Corporate Governance - The company has maintained an open but cautious approach towards mergers and acquisitions, monitoring market trends and potential integration opportunities [4]. - As of July 31, 2025, the number of shareholders stood at 10,088, indicating a stable investor base [5]. - On August 8, 2025, the net inflow of main funds was 3.85% of the total transaction value, reflecting investor interest in the company's stock [5].